EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
Neoadjuvant immunotherapy for locally advanced renal cell carcinoma currently shows limited benefit, as most trials are single‑arm, small, and recent Phase III studies such as PROSPER failed to demonstrate a survival advantage.
This article reviews the current status of neoadjuvant therapy for locally advanced renal cell carcinoma, summarizing the disappointing results of existing trials and underscoring the need for larger, adaptive randomized studies.
Optimizing neoadjuvant regimens could reduce tumor burden before surgery, improve surgical outcomes, and enhance long‑term survival for high‑risk renal cell carcinoma patients.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
- Metastatic Renal Cell Carcinoma: Which Patients Have the Best Outlook?